AKTS
Aktis Oncology, Inc. Common stock
Nasdaq · usd
Aktis Oncology, Inc. Common stock (AKTS) trades at $16.10 (-1.29%) as of 4:12:59 AM EST on Nov 19, 2026, +0.12% over the past month. Market cap is $898.35M, with 16.0 days to cover in short interest.
Stock performance
How Aktis Oncology, Inc. Common stock (AKTS) stock has performed from one day to one year, with its 52-week range.
- 1D
- -1.29%
- 1W
- -5.52%
- 1M
- +0.12%
- YTD
- -28.12%
- 1Y
- -28.12%
- 52-wk range
- $13.96 – $34.19
Key statistics
Today's trading snapshot for AKTS: day range, open, previous close, volume and market cap.
- Day range
- $16.08 – $16.71
- Open
- $16.30
- Prev close
- $16.31
- Volume
- 435.02K
- Market cap
- $898.35M
- Shares out
- 55.8M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Aktis Oncology, Inc. Common stock: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- 74.27
- P/B
- 1.96
- P/FCF
- —
- ROE
- -19.2%
- ROA
- -16.5%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Nov 18, 2026
8-K filings
Material corporate events Aktis Oncology, Inc. Common stock has disclosed to the SEC on Form 8-K.
- Quarterly earningsNov 12, 2026
On November 12, 2026, Aktis Oncology, Inc. issued a press release announcing its financial results and business highlights for the quarter ended September 30, 2026.
- Director departureApr 16, 2026
On April 15, 2026, each of Helen S. Kim and Oleg Nodelman notified the Board of their decision to resign from their respective positions as members of the Board and all committees thereof, effective as of May 20, 2026. Ms. Kim and Mr. Nodelman's resignations are not due to any disagreement with the Company relating to any of the Company's operations, policies or practices.
- Charter amendmentJan 12, 2026
The Company filed its amended and restated certificate of incorporation (the 'Amended and Restated Certificate') with the Secretary of State of the State of Delaware. The Amended and Restated Certificate amends and restates the Company's existing sixth amended and restated certificate of incorporation, as amended, in its entirety to, among other things: (i) authorize 480,000,000 shares of Common Stock and 10,000,000 shares of Class A common stock; (ii) eliminate all references to the previously-existing series of preferred stock; (iii) authorize 10,000,000 shares of undesignated preferred stock; (iv) require the approval of at least two-thirds of the shares entitled to vote to remove a director for cause; (v) establish a classified Board; and (vi) eliminate the ability of the Company's stockholders to take action by consent in lieu of a meeting.
- Voluntary bankruptcyDec 17, 2024
The Notice informed the Company that, pursuant to the discretionary authority granted to Nasdaq under Listing Rule 5110(b), the Company's previously disclosed seeking of voluntary protection under chapter 11 of the United States Bankruptcy Code would serve as an additional basis for delisting the Company's common stock.
- Debt accelerationDec 16, 2024
The filing of the Bankruptcy Petitions described in Item 1.03 above constitutes an event of default under the indenture (the "Indenture"), dated June 9, 2022, among the Company, Akoustis, Inc., as guarantor, and The Bank of New York Mellon Trust Company, N.A., as trustee (the "Trustee"), governing the Company's 6.0% Convertible Senior Notes due 2027 (the "Convertible Notes"). As of December 16, 2024, the aggregate, principal amount of outstanding Convertible Notes was $44,000,000. Pursuant to the Indenture, upon the occurrence of this event of default, all of the outstanding Convertible Notes became due and payable immediately without further action or notice.
Dividend history and stock splits
Aktis Oncology, Inc. Common stock's recent dividend payments and stock splits.
Dividends
No recent dividends.
Splits
- 1.094891-for-1Apr 24, 2015
AKTS short interest
How heavily AKTS is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 16.0
- Short interest
- 4.43M
- Avg volume
- 276.24K
As of · reported to FINRA twice monthly.
AKTS news
The latest news and headlines about Aktis Oncology, Inc. Common stock (AKTS).
- Does Aktis (AKTS) Have the Potential to Rally 105.62% as Wall Street Analysts Expect?positiveZacks Investment Research· Nov 11, 2026
- Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer CompanypositiveThe Motley Fool· May 13, 2026
- Aktis Oncology to Present at the BofA Securities Health Care ConferencepositiveGlobeNewswire Inc.· May 6, 2026
- Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingpositiveGlobeNewswire Inc.· Apr 21, 2026
- A Fresh IPO That Long-Term Investors Shouldn’t IgnorepositiveInvesting.com· Jan 14, 2026
Frequently asked questions
What is the Aktis Oncology, Inc. Common stock (AKTS) stock price today?
Aktis Oncology, Inc. Common stock (AKTS) is trading at $16.10 (-1.29% on the day) as of 4:12:59 AM EST on Nov 19, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Aktis Oncology, Inc. Common stock?
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies.
What is the short interest in AKTS?
As of Oct 30, 2026, AKTS has 4.43M shares short and 16.0 days to cover.
What exchange is AKTS listed on?
Aktis Oncology, Inc. Common stock (AKTS) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of AKTS with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a AKTS analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.